Papers
1
Total Citations
62
H-Index
1
About
No biography available yet.
Research Focus
Breast cancer1 · 62 citations
Cancer1 · 62 citations
Carcinoma1 · 62 citations
Chemotherapy1 · 62 citations
Cisplatin1 · 62 citations
Esophageal squamous cell carcinoma1 · 62 citations
Immunotherapy1 · 62 citations
Internal medicine1 · 62 citations
Medicine1 · 62 citations
Neoadjuvant therapy1 · 62 citations
Oncology1 · 62 citations
Paclitaxel1 · 62 citations
Key Achievements
1
H-Index
1
Papers
62
Total Citations
62
Avg Citations/Paper
🏆 Most Cited Paper
Safety and effectiveness of pembrolizumab combined with paclitaxel and cisplatin as neoadjuvant therapy followed by surgery for locally advanced resectable (stage III) esophageal squamous cell carcinoma: a study protocol for a prospective, single-arm, single-center, open-label, phase-II trial (Keystone-001)
62 citations · 2022
📈 Most Prolific Year: 2022 (1 Papers)
🤝 Key Collaborators: 13
🏛 Institutions: Tianjin Medical University Cancer Institute and Hospital
Top Papers
- 1
Key Collaborators
GZGang Zhao1 shared papersCCChuangui Chen1 shared papersZMZhao Ma1 shared papersWZWei‐Hong Zhang1 shared papersHJHongjing Jiang1 shared papersXSXiaobin Shang1 shared papersFLFei Liang1 shared papersJYJie Yue1 shared papersRLRunmei Li1 shared papersCZChen Zhang1 shared papersXDXiaofeng Duan1 shared papersLLLiang Liu1 shared papersBMBin Meng1 shared papers
Not generated yet